| Title: |
Invasive aspergillosis in liver transplant recipients in France (2007–21): a nationwide, retrospective, matched case–control study |
| Authors: |
Le Hyaric, Coralie; Melenotte, Cléa; Lefebvre, François; Saliba, Faouzi; Botterel, Françoise; El Domiaty, Nada; Dumortier, Jérôme; Persat, Florence; Do, Raphaël; Pasquier, Grégoire; Camus, Christophe; Gangneux, Jean-Pierre; Kamar, Nassim; Iriart, Xavier; Monsel, Antoine; Fekkar, Arnaud; Conti, Filomena; Vuotto, Fanny; Loridant, Séverine; Durand, François; Bonnal, Christine; Barbaz, Mathilde; Chesnay, Adélaïde; Vignals, Carole; Lefranc, Maxime; Guerin, Renaud; Moniot, Maxime; Weil, Delphine; Bellanger, Anne-Pauline; Decaens, Thomas; Maubon, Danièle; Lebossé, Fanny; Artzner, Thierry; Morel, Guillaume; Letscher-Bru, Valerie; Herbrecht, Raoul; Ader, Florence; Lortholary, Olivier; Lefort, Agnès; Guichon, Céline; Danion, François |
| Contributors: |
Hôpitaux Universitaires de Strasbourg (HUS); Université de Strasbourg (UNISTRA); Imagine - Institut des maladies génétiques (IHU) (Imagine - U1163); Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité); Hôpital Necker - Enfants Malades AP-HP; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP); Centre Médical de l'Institut Pasteur (CMIP); Institut Pasteur Paris (IP)-Université Paris Cité (UPCité); Hôpital Paul Brousse; AP-HP. Université Paris Saclay; Centre Hépato-Biliaire Hôpital Paul Brousse (CHB); AP-HP. Université Paris Saclay-AP-HP. Université Paris Saclay-Assistance Publique - Hôpitaux de Paris; Université Paris-Saclay; Hôpital Henri Mondor; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Henri Mondor Créteil; Groupe Henri Mondor-Albert Chenevier-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Groupe Henri Mondor-Albert Chenevier-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12); Helwan University; Hospices Civils de Lyon (HCL); Hôpital Edouard Herriot CHU - HCL; CHU Montpellier = Montpellier University Hospital; Centre Hospitalier Régional Universitaire Montpellier (CHRU Montpellier); Centre Hospitalier Universitaire Rennes; Institut de recherche en santé, environnement et travail (Irset); Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes (Biosit : Biologie - Santé - Innovation Technologique); Centre Hospitalier Universitaire de Toulouse (CHU Toulouse); Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity); Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Toulouse (EPE UT); Communauté d'universités et établissements de Toulouse (Comue de Toulouse)-Communauté d'universités et établissements de Toulouse (Comue de Toulouse); CHU Pitié-Salpêtrière AP-HP; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU); Centre Hospitalier Régional Universitaire CHU Lille (CHRU Lille); Unité de Glycobiologie Structurale et Fonctionnelle - UMR 8576 (UGSF); Université de Lille-Centre National de la Recherche Scientifique (CNRS); Hôpital Beaujon AP-HP; AP-HP - Hôpital Bichat - Claude Bernard Paris; Centre Hospitalier Régional Universitaire de Tours (CHRU Tours); CHU de Bordeaux Pellegrin Bordeaux; CHU Clermont-Ferrand; Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon); CHU de Grenoble-Alpes - Centre Hospitalier Universitaire CHU Grenoble (CHUGA); Hôpital de la Croix-Rousse CHU - HCL; Physiopathologie et Traitement des Maladies Hépatiques (PaThLiv); Université Claude Bernard Lyon 1 (UCBL); Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM); Institut de Cancérologie de Strasbourg Europe (ICANS); Hôpital Européen Fondation Ambroise Paré - Marseille; Centre Hospitalier Universitaire Strasbourg (CHU Strasbourg); Lyon Hépatologie Institute EVEREST Lyon; Immuno-Rhumatologie Moléculaire (IRM); Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM) |
| Source: |
ISSN: 2666-5247 ; The Lancet Microbe ; https://hal.science/hal-05538768 ; The Lancet Microbe, In press, pp.101272. ⟨10.1016/j.lanmic.2025.101272⟩. |
| Publisher Information: |
CCSD; Elsevier |
| Publication Year: |
2026 |
| Collection: |
Université Toulouse III - Paul Sabatier: HAL-UPS |
| Subject Terms: |
[SDV]Life Sciences [q-bio] |
| Description: |
International audience ; BackgroundInvasive aspergillosis is a rare but severe complication of liver transplantation. Incidence varies from 1·2% to 5·6% and mortality is greater than 50%. Few studies have investigated this complication. We aimed to describe cases of, and identify the factors associated with, invasive aspergillosis occurrence and mortality.MethodsThis nationwide, retrospective, matched case–control study included cases of invasive aspergillosis occurring after liver transplantation between Jan 1, 2007, and Dec 31, 2021, matched 1:1 on centre and transplantation period to control individuals without invasive aspergillosis across 15 liver transplantation centres in France. Cases were patients aged 18 years or older who presented with proven or probable invasive aspergillosis. The matched control was the next patient who received a transplant at the same transplantation centre after the case. Cases were retrospectively identified in each centre using the mycology laboratory database and the French Medicalised Information System Programme. Data were retrieved from hospital charts. The primary outcome was the identification of risk factors associated with the development of invasive aspergillosis following liver transplantation. Multivariable analysis using conditional logistic regression with a random effect for study centres was done to establish risk factors.FindingsAmong 14 332 liver transplantations, 196 recipients with invasive aspergillosis (62 [32%] female and 134 [68%] male) were identified and matched with 196 control individuals (54 [28%] female and 142 [73%] male). Invasive aspergillosis occurred at a median of 29 days (IQR 7–173) after liver transplantation. Risk factors for developing invasive aspergillosis were history of chronic kidney disease (adjusted odds ratio 4·13 [95% CI 2·35–7·24]), liver transplantation for acute liver disease (3·41 [1·44–8·06]), post-liver transplantation renal replacement therapy (3·82 [1·96–7·42]), and post-liver transplantation vasopressor support for ... |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| Relation: |
info:eu-repo/semantics/altIdentifier/pmid/41785881; PUBMED: 41785881 |
| DOI: |
10.1016/j.lanmic.2025.101272 |
| Availability: |
https://hal.science/hal-05538768; https://hal.science/hal-05538768v1/document; https://hal.science/hal-05538768v1/file/1-s2.0-S2666524725002009-main.pdf; https://doi.org/10.1016/j.lanmic.2025.101272 |
| Rights: |
https://creativecommons.org/licenses/by/4.0/ ; info:eu-repo/semantics/OpenAccess |
| Accession Number: |
edsbas.B4954BBA |
| Database: |
BASE |